AVITA Medical
Builds RECELL-based wound-care products for burns, trauma, and skin defects.
Something off on this page? Send us feedback.
Profile
Builds RECELL-based acute wound-care products and companion matrices for burns, traumatic wounds, and full-thickness skin defects. Revenue comes from hospital, treatment-center, and distributor sales, with a United States-heavy commercial base and reimbursement conditions shaping how approved uses are pursued.
Builds acute wound-care products around RECELL, a point-of-care system that prepares a patient's own Spray-On Skin Cells for thermal burns and full-thickness skin defects. The portfolio now also includes PermeaDerm and Cohealyx wound matrices, shifting the business from a RECELL-centered model toward a broader acute wound-care platform.
Revenue comes from products sold to hospitals, treatment centers, and distributors, plus lease revenue tied to RECELL GO processing devices. The business is concentrated in the United States and reported as one reporting segment.
Commercial execution depends on FDA-cleared indications, burn and trauma center adoption, reimbursement conditions, and partner rights for the matrix products. Vitiligo use is approved, but commercial investment is paused while procedure reimbursement remains limited and uncertain.
Company facts
Categories
Key statistics
Year to date +197% · Average volume (30d) 573.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | Lake Street | Reiterate | Buy | $6 | $12 | |
| Aug 19, 2026 | BTIG | Reiterate | Buy | $7 | $11 | |
| Aug 7, 2026 | BTIG | Upgrade | Neutral | Buy | $7 | |
| May 15, 2026 | Lake Street | Upgrade | Hold | Buy | $3.50 | $6 |
| Mar 26, 2026 | Northland Securities | Target | $10 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.29 | −$0.25 | +14.6% | $20.3M | $21.5M | +6.1% | +63.58% |
| May 14, 2026Q1 FY26 | −$0.35 | −$0.35 | 0.0% | $18.3M | $19.3M | +5.2% | +4.59% |
| Feb 12, 2026Q4 FY25 | −$0.36 | −$0.38 | −4.3% | $17.8M | $17.4M | −2.3% | +11.83% |
| Nov 6, 2025Q3 FY25 | −$0.43 | −$0.46 | −7.0% | $26.9M | $17.1M | −36.5% | +10.88% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $18.5M | $18.4M | $17.1M | $17.6M | $19.3M | $21.7M | |
| Gross profit | $15.7M | $14.9M | $13.9M | $14.3M | $15.7M | $17.8M | |
| Operating income | −$11.8M | −$11.1M | −$9.2M | −$10.4M | −$8.8M | −$6.9M | |
| Net income | −$13.9M | −$9.9M | −$13.2M | −$11.6M | −$10.6M | −$7.7M | |
| Diluted EPS | −$0.53 | −$0.38 | −$0.46 | −$0.38 | −$0.36 | −$0.25 | |
| Gross margin | 84.7% | 81.2% | 81.3% | 81.2% | 81.7% | 81.9% | |
| Operating margin | -63.9% | -60.5% | -53.6% | -59.1% | -45.7% | -31.6% |
Fiscal years (4-quarter sums)FY21 $33.0M · FY22 $34.4M · FY23 $50.1M · FY24 $64.3M · FY25 $71.6M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $11.1M · Total debt $48.5M · Total assets $47.8M · Shareholders' equity −$27.8M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 24.84M · Float 23.89M · 96.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Orbimed Advisors LLC | 41.04M | 165.22% | 13F | May 15, 2026 |
| Vanguard Capital Management LLC | 1.34M | 5.37% | 13F | May 15, 2026 |
| BlackRock, Inc. | 1.13M | 4.56% | 13F | May 13, 2026 |
| Geode Capital Management, LLC | 543.0K | 2.19% | 13F | May 15, 2026 |
| State Street Corp | 429.0K | 1.73% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 12, 2026 | David D. O'Toole | officer: CFO | +2,000 | $3.97 |
| Jun 9, 2026 | Joseph Fralin Woody | director | +15,200 | $4.13 |
| Jun 3, 2026 | Joseph Fralin Woody | director | +10,000 | $4.09 |
| May 20, 2026 | David D. O'Toole | officer: CFO | +2,000 | $4.26 |
| May 19, 2026 | David D. O'Toole | officer: CFO | +2,000 | $4.24 |
Peers
- Vericel
Severe-burn cell therapy and enzymatic debridement
- Integra LifeSciences
Dermal regeneration matrices for burns and complex wounds
- Organogenesis
Bioengineered skin substitutes and placental wound coverings
- MiMedx
Placental allografts for wound, burn and surgical care
- Smith & Nephew (ADR)
Global advanced wound platform with bioactives and NPWT
- Solventum
Negative-pressure wound therapy and wound dressings
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AVITA Medical | $10.35 | +0.39% | $257.1M | — | — | 3.4 | +78.6% |
| Vericel | $40.95 | 0.00% | $2.10B | 87.5 | 61.6 | 6.8 | +22.5% |
| Integra LifeSciences | $16.89 | 0.00% | $1.31B | — | 6.6 | 0.8 | +0.8% |
| Organogenesis | $1.74 | +0.29% | $223.9M | — | — | 0.5 | −56.7% |
| MiMedx | $4.50 | +0.22% | $655.9M | 112.5 | 91.3 | 1.8 | −34.7% |
| Smith & Nephew (ADR) | $28.72 | −0.93% | $12.17B | 19.2 | — | 1.9 | +3.7% |
| Solventum | $90.50 | −0.68% | $15.78B | 11.1 | 13.5 | 1.9 | +2.2% |
| Median | 53.4 | 37.6 | 1.9 | +1.5% |